Clinical Trial Update: Capacity of the Dual Combination Raltegravir/Etravirine to Maintain Virological Success in HIV-1 Infected Patients of at Least 45 Years of Age- ANRS 163 ETRAL [Phase 2]

View source ↗

Summary

Phase 2 ANRS 163 ETRAL trial evaluates whether dual therapy with raltegravir and etravirine maintains virological suppression in HIV-1–infected patients aged 45…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Etravirine (Intelence) (etravirine)
• Raltegravir (Isentress) (raltegravir)

Snippet

Sponsor: ANRS, Emerging Infectious Diseases | Conditions: HIV-1 Infection | Phase 2 | Status: COMPLETED | Results posted: 2021-02-05